| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.4 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.4 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.042 | 0.4 |